This module uses fundamental data of In Veritas to approximate the value of its Beneish M Score. In Veritas M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out In Veritas Piotroski F Score and In Veritas Altman Z Score analysis.
IVME
Beneish M Score
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Capex To Depreciation
Pb Ratio
Ev To Sales
Roic
Net Income Per Share
Payables Turnover
Research And Ddevelopement To Revenue
Capex To Revenue
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Current Ratio
Receivables Turnover
Debt To Equity
Revenue Per Share
Debt To Assets
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Free Cash Flow Per Share
Cash Per Share
Net Debt To E B I T D A
Graham Number
Capex Per Share
Average Receivables
Interest Debt Per Share
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Cash Ratio
Operating Cash Flow Sales Ratio
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Enterprise Value Multiple
Operating Cycle
Cash Conversion Cycle
Change In Cash
Net Borrowings
Total Cashflows From Investing Activities
Depreciation
Total Cash From Operating Activities
Change To Account Receivables
Change To Operating Activities
Net Income
Total Cash From Financing Activities
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Total Assets
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Retained Earnings
Accounts Payable
Long Term Debt
Net Receivables
Other Stockholder Equity
Total Liab
Short Long Term Debt
Total Current Assets
Intangible Assets
Common Stock
Property Plant Equipment
Selling General Administrative
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Probability Of Bankruptcy
At present, In Veritas' Debt To Assets are projected to increase based on the last few years of reporting. The current year's Interest Debt Per Share is expected to grow to 0.09, whereas Debt To Equity is forecasted to decline to (0.49). At present, In Veritas' Capex To Depreciation is projected to increase slightly based on the last few years of reporting. The current year's ROIC is expected to grow to 0.37, whereas PTB Ratio is forecasted to decline to (0.04).
At this time, In Veritas' M Score is unavailable. The earnings manipulation may begin if In Veritas' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by In Veritas executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of In Veritas' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if In Veritas' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between In Veritas' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards In Veritas in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find In Veritas' degree of accounting gimmicks and manipulations.
M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.
Total Assets
95,714.69
At present, In Veritas' Total Assets are projected to decrease significantly based on the last few years of reporting.
About In Veritas Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze In Veritas Medical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of In Veritas using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of In Veritas Medical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether In Veritas Medical is a strong investment it is important to analyze In Veritas' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact In Veritas' future performance. For an informed investment choice regarding IVME Stock, refer to the following important reports:
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of In Veritas. If investors know IVME will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about In Veritas listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.01)
Return On Assets
(6.48)
The market value of In Veritas Medical is measured differently than its book value, which is the value of IVME that is recorded on the company's balance sheet. Investors also form their own opinion of In Veritas' value that differs from its market value or its book value, called intrinsic value, which is In Veritas' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because In Veritas' market value can be influenced by many factors that don't directly affect In Veritas' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between In Veritas' value and its price as these two are different measures arrived at by different means. Investors typically determine if In Veritas is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, In Veritas' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.